IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to investigate the safety and effectiveness of
botulinum toxin A (Xeomin) ® injections in patients who suffer from focal pain in areas of
radiation and/or surgery as a result of cancer treatment. Our hypothesis is that injection of
incobotulinum toxin A into an area of local pain, at or around the area of a
post-surgical/post radiation scar, relieves the focal cancer pain.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Merz North America, Inc. Merz Pharmaceuticals, LLC
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA